Skip to main content

Articles

Page 4 of 64

  1. Gemcitabine (GEM) is the first-line chemotherapeutic drug used to treat pancreatic ductal adenocarcinoma carcinoma (PDAC), but chemoresistance is often encountered clinically. Nrf2, an oxidative stress respons...

    Authors: Juan Zhang, Hong-Xi Xu, William Chi Shing Cho, Wah Cheuk, Yang Li, Qiong-Hui Huang, Wen Yang, Yan-Fang Xian and Zhi-Xiu Lin
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:90
  2. Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma in which microenvironmental (niche) factors promote PDAC progression. In mouse models, reduction of the stroma increased the proporti...

    Authors: Tomohiko Shinkawa, Kenoki Ohuchida, Yuki Mochida, Kukiko Sakihama, Chika Iwamoto, Toshiya Abe, Noboru Ideno, Yusuke Mizuuchi, Koji Shindo, Naoki Ikenaga, Taiki Moriyama, Kohei Nakata, Yoshinao Oda and Masafumi Nakamura
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:89
  3. Resistance to standard therapy is a major reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Developing novel therapy to overcome PDAC drug-resistance is urgently needed. CRABP-II was hi...

    Authors: Shuiliang Yu, Lei Wang, Danian Che, Mei Zhang, Ming Li, Mikihiko Naito, Wei Xin and Lan Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:88
  4. Epigenetic regulations frequently appear in Glioblastoma (GBM) and are highly associated with metabolic alterations. Especially, Histone deacetylases (HDACs) correlates with the regulation of tumorigenesis and...

    Authors: Sungmin Kwak, Seung-Ho Park, Sung-Hak Kim, Gi-Jun Sung, Ji-Hye Song, Ji-Hoon Jeong, Hyunhee Kim, Chang Hoon Ha, Seong Who Kim and Kyung-Chul Choi
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:87
  5. Circulating tumor cells (CTCs) are responsible for the metastatic dissemination of colorectal cancer (CRC) to the liver, lungs and lymph nodes. CTCs rarity and heterogeneity strongly limit the elucidation of t...

    Authors: Maria Laura De Angelis, Federica Francescangeli, Chiara Nicolazzo, Michele Signore, Alessandro Giuliani, Lidia Colace, Alessandra Boe, Valentina Magri, Marta Baiocchi, Antonio Ciardi, Francesco Scarola, Massimo Spada, Filippo La Torre, Paola Gazzaniga, Mauro Biffoni, Ruggero De Maria…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:86
  6. Multiple myeloma (MM) is an incurable plasma cell malignancy in the bone marrow (BM), while immunoglobulin D type of MM (IgD MM) is a very rare but most severe subtype in all MM cases. Therefore, systemic stud...

    Authors: Xiaozhu Tang, Zhendong Deng, Pinggang Ding, Wanting Qiang, Yue Lu, Shengyao Gao, Ye Hu, Ye Yang, Juan Du and Chunyan Gu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:85
  7. Pancreatic ductal adenocarcinoma (PDAC) represents an unmet clinical need due to the very poor prognosis and the lack of effective therapy. Here we investigated the potential of domatinostat (4SC-202), a new c...

    Authors: Maria Serena Roca, Tania Moccia, Federica Iannelli, Cristina Testa, Carlo Vitagliano, Michele Minopoli, Rosa Camerlingo, Giulia De Riso, Rossella De Cecio, Francesca Bruzzese, Mariarosaria Conte, Lucia Altucci, Elena Di Gennaro, Antonio Avallone, Alessandra Leone and Alfredo Budillon
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:83

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2022 41:138

  8. BCR-ABL-independent drug resistance is a barrier to curative treatment of chronic myeloid leukemia (CML). However, the molecular pathways underlying BCR-ABL-independent tyrosine kinase inhibitor (TKI) resistan...

    Authors: Taewoo Yang, Kyu-Young Sim, Gwang-Hoon Ko, Jae-Sook Ahn, Hyeoung-Joon Kim and Sung-Gyoo Park
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:82
  9. Tumor budding is included in the routine diagnosis of colorectal cancer (CRC) and is considered a tumor prognostic factor independent of TNM staging. This study aimed to identify the fibroblast-mediated effect...

    Authors: Ling-Fang Gao, Yan Zhong, Ting Long, Xia Wang, Jia-Xian Zhu, Xiao-Yan Wang, Zhi-Yan Hu and Zu-Guo Li
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:81
  10. Impaired p53 function is one of the central molecular features of a tumor cell and even a partial reduction in p53 activity can increase the cancer risk in mice and men. From a therapeutic perspective it is no...

    Authors: Boris Klimovich, Laura Meyer, Nastasja Merle, Michelle Neumann, Alexander M. König, Nikolaos Ananikidis, Corinna U. Keber, Sabrina Elmshäuser, Oleg Timofeev and Thorsten Stiewe
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:80
  11. Dysfunctional p53 signaling is one of the major causes of hepatocellular carcinoma (HCC) tumorigenesis and development, but the mechanisms underlying p53 inactivation in HCC have not been fully clarified. The ...

    Authors: Xiuyuan Zhang, Qijian Zheng, Xiuying Yue, Zhanna Yuan, Jiming Ling, Yanzhi Yuan, Yanying Liang, Aihua Sun, Yuchen Liu, Hui Li, Kaikun Xu, Fuchu He, Jian Wang, Jin Wu, Chunling Zhao and Chunyan Tian
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:79
  12. Progression to stage IV disease remains the main cause of breast cancer-related deaths. Increasing knowledge on the hematogenous phase of metastasis is key for exploiting the entire window of opportunity to in...

    Authors: Emanuela Fina, Loredana Cleris, Matteo Dugo, Mara Lecchi, Chiara Maura Ciniselli, Daniele Lecis, Giulia Valeria Bianchi, Paolo Verderio, Maria Grazia Daidone and Vera Cappelletti
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:78
  13. Metabolic reprogramming is a hallmark of cancer. However, the roles of long noncoding RNAs (lncRNAs) in cancer metabolism, especially glucose metabolism remain largely unknown.

    Authors: Baoyu He, Hongli Pan, Fengque Zheng, Saiqiong Chen, Qingli Bie, Jinghe Cao, Rou Zhao, Jing Liang, Li Wei, Jianchao Zeng, Hui Li, Xing Cui, Yixuan Ding, Wei Chao, Tiantian Xiang, Yuhe Cheng…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:77
  14. Mitochondrial dynamics homeostasis is important for cell metabolism, growth, proliferation, and immune responses. The critical GTPase for mitochondrial fission, Drp1 is frequently upregulated in many cancers a...

    Authors: Yujia Li, Hui Chen, Qi Yang, Lixin Wan, Jing Zhao, Yuanyuan Wu, Jiaxin Wang, Yating Yang, Menglan Niu, Hongliang Liu, Junqi Liu, Hushan Yang, Shaogui Wan, Yanming Wang and Dengke Bao
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:76
  15. The combination of pemetrexed and cisplatin remains the reference first-line systemic therapy for malignant pleural mesothelioma (MPM). Its activity is moderate because of tumor aggressiveness, immune-suppress...

    Authors: Iris Chiara Salaroglio, Dimas Carolina Belisario, Paolo Bironzo, Preeta Ananthanarayanan, Luisa Ricci, Sabrina Digiovanni, Simona Fontana, Francesca Napoli, Alberto Sandri, Chiara Facolmatà, Roberta Libener, Valentina Comunanza, Federica Grosso, Elena Gazzano, Francesco Leo, Riccardo Taulli…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:75
  16. Glioblastoma (GB) is the most common and highly malignant brain tumor characterized by aggressive growth and resistance to alkylating chemotherapy. Autophagy induction is one of the hallmark effects of anti-GB...

    Authors: Zhuang Li, Wen-Juan Fu, Xiao-Qing Chen, Shuai Wang, Ru-Song Deng, Xiao-Peng Tang, Kai-Di Yang, Qin Niu, Hong Zhou, Qing-Rui Li, Yong Lin, Mei Liang, Si-Si Li, Yi-Fang Ping, Xin-Dong Liu, Xiu-Wu Bian…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:74
  17. Integrin alpha 2 (ITGA2) has been recently reported to be an oncogene and to play crucial roles in tumor cell proliferation, invasion, metastasis, and angiogenesis. Our previous study showed that ITGA2 was ove...

    Authors: Hongkun Cai, Feng Guo, Shuang Wen, Xin Jin, Heshui Wu and Dianyun Ren
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:73
  18. Authors: Linglong Yin, Youhong Liu, Yuchong Peng, Yongbo Peng, Xiaohui Yu, Yingxue Gao, Bowen Yuan, Qianling Zhu, Tuoyu Cao, Leye He, Zhicheng Gong, Lunquan Sun, Xuegong Fan and Xiong Li
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:72

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:153

  19. Pancreatic ductal adenocarcinoma (PDAC) is characterized by clusters of cancer cells surrounded by a dense desmoplastic stroma. However, little is known about stromal cell heterogeneity in the pancreatic tumor...

    Authors: Shangyou Zheng, Chonghui Hu, Hongcao Lin, Guolin Li, Renpeng Xia, Xiang Zhang, Dan Su, Zhihua Li, Quanbo Zhou and Rufu Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:71
  20. Resistance of colorectal cancer (CRC) cells to radiotherapy considerably contributes to poor clinical outcomes of CRC patients. Microarray profiling in this study revealed the differentially expressed forkhead...

    Authors: Mei Yang, Qian Liu, Maolin Dai, Renqun Peng, Xinghui Li, Wei Zuo, Juhua Gou, Feixue Zhou, Shuangjiang Yu, Hao Liu and Min Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:70
  21. Glycolysis is a pivotal process in metabolic reprogramming of tumorigenesis. Previous research has indicated that lncRNAs might play crucial roles in glycolysis of various tumors. However, the function of lncR...

    Authors: Yuhang Hu, Jiang Tang, Fengyu Xu, Jinhuang Chen, Zhu Zeng, Shengbo Han, Fan Wang, Decai Wang, Mengqi Huang, Yong Zhao, Yan Huang, Wenfeng Zhuo and Gang Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:69
  22. Epidemiological studies have confirmed that abnormal circadian rhythms are associated with tumorigenesis in breast cancer. However, few studies have investigated the pathological roles of rhythm genes in breas...

    Authors: Weiwei Yang, Jing Li, Minghui Zhang, Haichuan Yu, Yuan Zhuang, Lingyu Zhao, Lili Ren, Jinan Gong, Hongjie Bi, Lixuan Zeng, Yang Xue, Jinjin Yang, Yan Zhao, Shuoshuo Wang, Shuangshu Gao, Zitong Fu…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:67
  23. The interaction between programmed death receptor (PD-1) and its ligand (PD-L1) is essential for suppressing activated T-lymphocytes. However, the precise mechanisms underlying PD-L1 overexpression in tumours ...

    Authors: Yanyan Zhang, Shuyi Zhu, Yuanyuan Du, Fan Xu, Wenbo Sun, Zhi Xu, Xiumei Wang, Peipei Qian, Qin Zhang, Jifeng Feng and Yong Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:66
  24. Intrahepatic Cholangiocarcinoma (iCCA) is characterized by a strong stromal reaction playing a role in tumor progression. Thymus cell antigen 1 (THY1), also called Cluster of Differentiation 90 (CD90), is a key r...

    Authors: Serena Mancarella, Grazia Serino, Isabella Gigante, Antonio Cigliano, Silvia Ribback, Paola Sanese, Valentina Grossi, Cristiano Simone, Raffaele Armentano, Matthias Evert, Diego F. Calvisi and Gianluigi Giannelli
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:65
  25. Ion channels are emerging as promising oncological targets. The potassium channels Kv1.3 and IKCa are highly expressed in the plasma membrane and mitochondria of human chronic lymphocytic leukemia (CLL) cells,...

    Authors: Filippo Severin, Andrea Urbani, Tatiana Varanita, Magdalena Bachmann, Michele Azzolini, Veronica Martini, Marco Pizzi, Angelo Paolo Dei Tos, Federica Frezzato, Andrea Mattarei, Paolo Ghia, Maria Teresa Sabrina Bertilaccio, Erich Gulbins, Cristina Paradisi, Mario Zoratti, Gianpietro Carlo Semenzato…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:64
  26. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-021-02052-z.

    Authors: Haiyong Zhang, Jing Wu, Jinqiu Yuan, Huafu Li, Yawei Zhang, Wang Wu, Wei Chen, Chunming Wang, Sijun Meng, Songyao Chen, Mingyu Huo, Yulong He and Changhua Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:63
  27. Immunotherapy has emerged as a promising strategy for boosting antitumoral immunity. Blockade of immune checkpoints (ICs), which regulate the activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) ...

    Authors: Adrià Archilla-Ortega, Carla Domuro, Juan Martin-Liberal and Purificación Muñoz
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:62
  28. Colorectal cancer is one of the most frequent and deadly tumors. Among the key regulators of CRC growth and progression, the microenvironment has emerged as a crucial player and as a possible route for the dev...

    Authors: Eva Andreuzzi, Albina Fejza, Maurizio Polano, Evelina Poletto, Lucrezia Camicia, Greta Carobolante, Giulia Tarticchio, Federico Todaro, Emma Di Carlo, Melania Scarpa, Marco Scarpa, Alice Paulitti, Alessandra Capuano, Vincenzo Canzonieri, Stefania Maiero, Mara Fornasarig…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:60
  29. Head and Neck cancer (HNC) is a fatal malignancy with poor prognosis. Human Papillomavirus (HPV) infection is becoming the prominent cause of HNC in the western world, and studying the molecular mechanisms und...

    Authors: Simona Citro, Claudia Miccolo, Alessandro Medda, Lavinia Ghiani, Marta Tagliabue, Mohssen Ansarin and Susanna Chiocca
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:59
  30. Accurate predictions of tumor dissemination risks and medical treatment outcomes are critical to personalize therapy. Patient-derived xenograft (PDX) models in mice have demonstrated high accuracy in predictin...

    Authors: Zaheer Ali, Malin Vildevall, Gabriela Vazquez Rodriguez, Decky Tandiono, Ioannis Vamvakaris, Georgios Evangelou, Georgios Lolas, Konstantinos N. Syrigos, Alberto Villanueva, Michael Wick, Shenga Omar, Anna Erkstam, Julia Schueler, Anna Fahlgren and Lasse D. Jensen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:58
  31. Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell deat...

    Authors: Lingyue Liu, Xing Huang, Fukang Shi, Jinyuan Song, Chengxiang Guo, Jiaqi Yang, Tingbo Liang and Xueli Bai
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:56
  32. Authors: Shou-Hua Wang, Fei Ma, Zhao-hui Tang, Xiao-Cai Wu, Qiang Cai, Ming-Di Zhang, Ming-Zhe Weng, Di Zhou, Jian-Dong Wang and Zhi-Wei Quan
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:55

    The original article was published in Journal of Experimental & Clinical Cancer Research 2016 35:160

  33. Molecular mechanisms underlying inflammation-associated breast tumor growth are poorly studied. S100A7, a pro-inflammatory molecule has been shown to enhance breast cancer growth and metastasis. However, the S...

    Authors: Sanjay Mishra, Manish Charan, Rajni Kant Shukla, Pranay Agarwal, Swati Misri, Ajeet K. Verma, Dinesh K. Ahirwar, Jalal Siddiqui, Kirti Kaul, Neety Sahu, Kunj Vyas, Ayush Arpit Garg, Anum Khan, Wayne O. Miles, Jonathan W. Song, Nidhi Bhutani…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:54
  34. Chloride intracellular channel-1 (CLIC1) activity controls glioblastoma proliferation. Metformin exerts antitumor effects in glioblastoma stem cells (GSCs) inhibiting CLIC1 activity, but its low potency hamper...

    Authors: Federica Barbieri, Alessia Graziana Bosio, Alessandra Pattarozzi, Michele Tonelli, Adriana Bajetto, Ivan Verduci, Francesca Cianci, Gaetano Cannavale, Luca M. G. Palloni, Valeria Francesconi, Stefano Thellung, Pietro Fiaschi, Samanta Mazzetti, Silvia Schenone, Beatrice Balboni, Stefania Girotto…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:53
  35. Authors: Kausik Bishayee, Khadija Habib, Uddin Md. Nazim, Jieun Kang, Aniko Szabo, Sung‑ Oh Huh and Ali Sadra
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:52

    The original article was published in Journal of Experimental & Clinical Cancer Research 2022 41:18

  36. Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK)...

    Authors: Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, S. Percy Ivy, Lisa Wang…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:51
  37. High-grade serous ovarian cancer (HGSOC) has poor survival rates due to a combination of diagnosis at advanced stage and disease recurrence as a result of chemotherapy resistance. In BRCA1 (Breast Cancer gene ...

    Authors: Marianna Buttarelli, Alessandra Ciucci, Fernando Palluzzi, Giuseppina Raspaglio, Claudia Marchetti, Emanuele Perrone, Angelo Minucci, Luciano Giacò, Anna Fagotti, Giovanni Scambia and Daniela Gallo
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:50
  38. Therapy resistance, which leads to the development of loco-regional relapses and distant metastases after treatment, constitutes one of the major problems that head and neck squamous cell carcinoma (HNSCC) pat...

    Authors: Elisa Rioja-Blanco, Irene Arroyo-Solera, Patricia Álamo, Isolda Casanova, Alberto Gallardo, Ugutz Unzueta, Naroa Serna, Laura Sánchez-García, Miquel Quer, Antonio Villaverde, Esther Vázquez, Xavier León, Lorena Alba-Castellón and Ramon Mangues
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:49
  39. Perineural invasion (PNI) and autophagy are two common features in the tumor microenvironment of pancreatic cancer (PanCa) and have a negative effect on prognosis. Potential mediator cells and the molecular me...

    Authors: Wunai Zhang, Rui He, Wenbin Yang, Yan Zhang, Qinggong Yuan, Jixin Wang, Yang Liu, Shuo Chen, Simei Zhang, Weifan Zhang, Zeen Zhu, Jing Zhang, Zheng Wang and Junhui Li
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:48
  40. Glioblastoma (GBM) is the most aggressive and lethal brain tumor. Although the histone deacetylase (HDAC)/transcription factor axis promotes growth in GBM, whether HDACs including HDAC6 are involved in modulat...

    Authors: An-Chih Wu, Wen-Bin Yang, Kwang-Yu Chang, Jung-Shun Lee, Jing-Ping Liou, Ruei-Yuan Su, Siao Muk Cheng, Daw-Yang Hwang, Ushio Kikkawa, Tsung-I Hsu, Chih-Yang Wang, Wen-Chang Chang, Pin-Yuan Chen and Jian-Ying Chuang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:47
  41. Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activati...

    Authors: Lina Merkens, Verena Sailer, Davor Lessel, Ella Janzen, Sarah Greimeier, Jutta Kirfel, Sven Perner, Klaus Pantel, Stefan Werner and Gunhild von Amsberg
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:46
  42. Multiple myeloma (MM) remains an incurable cancer despite advances in therapy. Therefore, the search for new targets is still essential to uncover potential treatment strategies. Metabolic changes, induced by ...

    Authors: Inge Oudaert, Hatice Satilmis, Philip Vlummens, Wouter De Brouwer, Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquière, Karin Vanderkerken, Kim De Veirman and Eline Menu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:45
  43. Tumor cell metabolic reprogramming is crucial for the malignant behavior of cancer cells by promoting their proliferation. However, little is known on how transient receptor potential 7 (TRPM7) modulates metab...

    Authors: Yongchang Chen, Lu Liu, Longzheng Xia, Nayiyuan Wu, Ying Wang, He Li, Xue Chen, Xiaoye Zhang, Zhaoyi Liu, Miaochen Zhu, Qianjin Liao and Jing Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:44
  44. Targeting mitochondrial oncoproteins presents a new concept in the development of effective cancer therapeutics. ATAD3A is a nuclear-encoded mitochondrial enzyme contributing to mitochondrial dynamics, cholest...

    Authors: Liwei Lang, Reid Loveless, Juan Dou, Tiffany Lam, Alex Chen, Fang Wang, Li Sun, Jakeline Juarez, Zhaohui Steve Qin, Nabil F. Saba, Chloe Shay and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:43
  45. N6-methyladenosine (m6A) modification is the most common chemical modification in mammalian mRNAs, and it plays important roles by regulating several cellular processes. Previous studies report that m6A is implic...

    Authors: Jiapeng Huang, Wei Sun, Zhihong Wang, Chengzhou Lv, Ting Zhang, Dalin Zhang, Wenwu Dong, Liang Shao, Liang He, Xiaoyu Ji, Ping Zhang and Hao Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:42
  46. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Ilaria Romito, Manuela Porru, Maria Rita Braghini, Luca Pompili, Nadia Panera, Annalisa Crudele, Daniela Gnani, Cristiano De Stefanis, Marco Scarsella, Silvia Pomella, Stefano Levi Mortera, Emmanuel de Billy, Adrian Libenzio Conti, Valeria Marzano, Lorenza Putignani, Manlio Vinciguerra…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:40

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:364

Annual Journal Metrics